Cerus Corp (CERS) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.
the bull case· 4
11
supplier and customer relationships disclosed in regulatory filings
sec filingsedgar4
fund managers on file reporting a position
n-portas of Jun 30 '26184
managers reporting positions in regular regulatory filings
13fJun 30 '2624
managers whose positions together form the bulk of reported value
13fJun 30 '26the bear case· 4
10 of 24
largest reporting managers that reduced their stakes in the latest quarter
13fJun 30 '26−0.37%
net change in shares held by the largest reporting managers this quarter
13fJun 30 '260.30%
largest disclosed fund weight represented by a single ETF holding
n-portApr 30 '266 of 8
recent reported moves that came in below options implied ranges
earnings historyimplied vs realizedSides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 3 '26 report. Not a forecast, not advice.
Of the 6 companies Cerus Corp moves with most closely, none share its SEC classification.
Measured against 499 trading days of our own closes. Co-movement, not cause.
SIC 3841, Surgical & Medical Instruments & Apparatus, from each company's own filings. Largest first.
High 2.66 at 3:45 pm ET, low 2.60 at 9:30 am ET.
Cerus Corp
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Surgical & Medical Instruments & Apparatus
tall tick = annual report · 1 on record
CERS (Cerus Corp) has 5 disclosed suppliers and 6 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.
183 managers report a position worth $439.4M between them, and 24 of them hold 80% of it.